<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35468904</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The novel adamantane derivatives as potential mediators of inflammation and neural plasticity in diabetes mice with cognitive impairment.</ArticleTitle>
        <Pagination>
          <StartPage>6708</StartPage>
          <MedlinePgn>6708</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">6708</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-10187-y</ELocationID>
        <Abstract>
          <AbstractText>Diabetes is a chronic disease leading to memory difficulties and deterioration of learning abilities. The previous studies showed that modulation of inflammatory pathways in the diabetic brain may reduce dysfunction or cell death in brain areas which are important for control of cognitive function. In the present study, we investigated the neuroprotective actions of newly synthesized adamantane derivatives on diabetes-induced cognitive impairment in mice. Our study relied on the fact that both vildagliptin and saxagliptin belong to DPP4 inhibitors and, contain adamantanyl group. Efficacy of tested compounds at reversing diabetes-induced different types of memory impairment was evaluated with the use of selected behavioural tests. The following neuroinflammatory indicators were also analyzed: neuroinflammatory indicators and the expression of genes involved in the inflammatory response of brain (Cav1, Bdnf). Our study demonstrated that new adamantane derivatives, similarly to DPP4 inhibitors, can restrict diabetes-induced cognitive deficits. We demonstrated that the overexpression of GLP-1-glucagon-like peptide as well as Bdnf, Cav1 genes translate into central blockade of pro-inflammatory synthesis of cytokines and significantly improvement on memory performance in diabetes mice. Newly synthesized adamantane derivatives might have important roles in prevention and treatment of cognitive impairment by inflammatory events in patients with diabetes or related diseases.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Piątkowska-Chmiel</LastName>
            <ForeName>Iwona</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland. iwona.piatkowska-chmiel@umlub.pl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gawrońska-Grzywacz</LastName>
            <ForeName>Monika</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Popiołek</LastName>
            <ForeName>Łukasz</ForeName>
            <Initials>Ł</Initials>
            <AffiliationInfo>
              <Affiliation>Chair and Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki Street, 20-093, Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herbet</LastName>
            <ForeName>Mariola</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dudka</LastName>
            <ForeName>Jarosław</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Chair and Department of Toxicology, Faculty of Pharmacy, Medical University of Lublin, 8b Jaczewskiego Street, 20-090, Lublin, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="Y">Adamantane</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="Y">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>5</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35468904</ArticleId>
        <ArticleId IdType="pmc">PMC9035983</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-10187-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-10187-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels,Belgium: 2019. https://www.diabetesatlas.org (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>Tesfaye S, et al.  Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005;352:341–350. doi: 10.1056/NEJMoa032782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa032782</ArticleId>
            <ArticleId IdType="pubmed">15673800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, et al.  Aging exacerbates impairments of cerebral blood flow autoregulation and cognition in diabetic rats. GeroScience. 2020;42:1387–1410. doi: 10.1007/s11357-020-00233-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11357-020-00233-w</ArticleId>
            <ArticleId IdType="pmc">PMC7525432</ArticleId>
            <ArticleId IdType="pubmed">32696219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayeda ER, Whitmer RA, Yaffe K. Diabetes and cognition. Clin. Geriatr. Med. 2015;31:101–115. doi: 10.1016/j.cger.2014.08.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cger.2014.08.021</ArticleId>
            <ArticleId IdType="pmc">PMC4370221</ArticleId>
            <ArticleId IdType="pubmed">25453304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balasubramanian, P. et al. Time-restricted feeding (TRF) for prevention of age-related vascular cognitive impairment and dementia. Ageing Res. Rev.64, 101189. 10.1016/j.arr.2020.101189 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: From glucose metabolism to neurodegeneration. Exp. Diabesity Res. 2003;4:303–312. doi: 10.1155/EDR.2003.303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/EDR.2003.303</ArticleId>
            <ArticleId IdType="pmc">PMC2478613</ArticleId>
            <ArticleId IdType="pubmed">14668051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadeghi, A., Hami, J., Razavi, S., Esfandiary, E &amp; Hejazi, Z. The effect of diabetes mellitus on apoptosis in hippocampus: cellular and molecular aspects. Int. J. Prev. Med. 7, 57. 10.4103/2008-7802.178531 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Chung WS, Walijski CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci. 2015;18:1539–1545. doi: 10.1038/nn.4142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.4142</ArticleId>
            <ArticleId IdType="pmc">PMC4739631</ArticleId>
            <ArticleId IdType="pubmed">26505565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piatkowska-Chmiel I, Herbet M, Gawronska-Grzywacz M, Ostrowska-Lesko M, Dudka J. The role of molecular and inflammatory indicators in the assessment of cognitive dysfunction in a mouse model of diabetes. Int. J. Mol. Sci. 2021;22:3878. doi: 10.3390/ijms22083878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22083878</ArticleId>
            <ArticleId IdType="pmc">PMC8069936</ArticleId>
            <ArticleId IdType="pubmed">33918576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bomba M, et al.  Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neur. Aging. 2018;64:33–43. doi: 10.1016/j.neurobiolaging.2017.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.12.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. 2009;106:1285–1290. doi: 10.1073/pnas.0806720106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0806720106</ArticleId>
            <ArticleId IdType="pmc">PMC2633544</ArticleId>
            <ArticleId IdType="pubmed">19164583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harkavyi A, et al.  Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflamm. 2008;5:1–9. doi: 10.1186/1742-2094-5-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1742-2094-5-19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. Alzheimers Dement. 2014;10:12–25. doi: 10.1016/j.jalz.2013.12.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2013.12.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradbury J. Hope for AD with NGF gene-therapy trial. 2005 doi: 10.1016/S1474-4422(05)70086-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(05)70086-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YS, et al.  Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetol. 2012;55:2456–2468. doi: 10.1007/s00125-012-2592-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-012-2592-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>During MJ, et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 2003;9:1173–1179. doi: 10.1038/nm919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm919</ArticleId>
            <ArticleId IdType="pubmed">12925848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drug. 2012;26:871–882. doi: 10.2165/11635890-000000000-00000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11635890-000000000-00000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin XY, et al.  Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease: a meta-analysis study (N = 7277) Mol. Psychiatry. 2017;22:312–320. doi: 10.1038/mp.2016.62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mp.2016.62</ArticleId>
            <ArticleId IdType="pubmed">27113997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krabbe KS, et al.  Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia. 2007;50:431–438. doi: 10.1007/s00125-006-0537-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00125-006-0537-4</ArticleId>
            <ArticleId IdType="pubmed">17151862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luchsinger JA, et al.  Relation of diabetes to mild cognitive impairment. Arch. Neurol. 2007;64:570–575. doi: 10.1001/archneur.64.4.570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.64.4.570</ArticleId>
            <ArticleId IdType="pubmed">17420320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng T, et al.  Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the China national diabetes and metabolic disorders study. J. Clin. Endocrinol. Metab. 2014;99:E2330–E2334. doi: 10.1210/jc.2014-1480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1480</ArticleId>
            <ArticleId IdType="pubmed">25029421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng T, et al.  Increased plasma DPP4 activities predict new-onset hyperglycemia in Chinese over a four-year period: possible associations with inflammation. Metabolism. 2015;64:498–505. doi: 10.1016/j.metabol.2014.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.metabol.2014.12.004</ArticleId>
            <ArticleId IdType="pubmed">25592717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng T, et al.  Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metabolism. 2018;8:7105–7112.</Citation>
        </Reference>
        <Reference>
          <Citation>Tian L, et al.  Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in non-obese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology. 2010;151:3049–3060. doi: 10.1210/en.2010-0068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2010-0068</ArticleId>
            <ArticleId IdType="pubmed">20444936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: Medicinal chemistry of adamantane derivatives. Chem. Rev. 2013;113:3516–3604. doi: 10.1021/cr100264t.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cr100264t</ArticleId>
            <ArticleId IdType="pmc">PMC3650105</ArticleId>
            <ArticleId IdType="pubmed">23432396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, et al.  Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010;584:3359–3365. doi: 10.1016/j.febslet.2010.06.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2010.06.025</ArticleId>
            <ArticleId IdType="pubmed">20600002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller T, Kuhn W, Möhr JD. Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia. Expert Opin. Pharmacother. 2019;20:1181–1187. doi: 10.1080/14656566.2019.1612365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14656566.2019.1612365</ArticleId>
            <ArticleId IdType="pubmed">31058557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsunaga S, et al.  The efficacy and safety of memantine for the treatment of Alzheimer’s disease. Expert Opin. Drug Saf. 2018;17:1053–1061. doi: 10.1080/14740338.2018.1524870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14740338.2018.1524870</ArticleId>
            <ArticleId IdType="pubmed">30222469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giacino JT, et al.  Placebo-controlled trial of amantadine for severe traumatic brain injury. N. Engl. J. Med. 2012;366:819–826. doi: 10.1056/NEJMoa1102609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1102609</ArticleId>
            <ArticleId IdType="pubmed">22375973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao, Y., Zhang, Y., Li, Z., Ma, L. &amp; Yang, J. Persistent vegetative state after severe cerebral hemorrhage treated with amantadine: A retrospective controlled study. Medicine99, e21822. 10.1097/MD.0000000000021822 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Abdelsalam RM, Safar MM. Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease model: Role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways. J. Neurochem. 2015;133:700–707. doi: 10.1111/jnc.13087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.13087</ArticleId>
            <ArticleId IdType="pubmed">25752913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wicinski, M. et al. Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases. Int. J. Mol. Sci. 20, 4052. 10.3390/ijms20164052 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Satoh-Asahara N, et al.  A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62:347–351. doi: 10.1016/j.metabol.2012.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.metabol.2012.09.004</ArticleId>
            <ArticleId IdType="pubmed">23062489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makdissi A, et al.  Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 2012;97:3333–3341. doi: 10.1210/jc.2012-1544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-1544</ArticleId>
            <ArticleId IdType="pmc">PMC3431580</ArticleId>
            <ArticleId IdType="pubmed">22745245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CH, et al.  Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses. Mol. Neurobiol. 2018;55:3007–3020. doi: 10.1007/s12035-017-0550-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-017-0550-2</ArticleId>
            <ArticleId IdType="pubmed">28456941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka JI. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci. Res. 2006;55:352–360. doi: 10.1016/j.neures.2006.04.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2006.04.008</ArticleId>
            <ArticleId IdType="pubmed">16720054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulkowski G, Dabrowska-Bouta B, Chalimoniuk M, Struzynska L. Effects of antagonists of glutamate receptors on pro-inflammatory cytokines in the brain cortex of rats subjected to experimental autoimmuneencephalomyelitis. J. Neuroimmunol. 2013;261:67–76. doi: 10.1016/j.jneuroim.2013.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.05.006</ArticleId>
            <ArticleId IdType="pubmed">23746391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isik AT, Soysal P, Yay A, Usarel C. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res. Clin. Pract. 2017;123:192–198. doi: 10.1016/j.diabres.2016.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2016.12.010</ArticleId>
            <ArticleId IdType="pubmed">28056430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pintana H, Apaijai N, Chattipakorn N, Chattipakorn SC. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 2013;218:1–11. doi: 10.1530/JOE-12-0521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JOE-12-0521</ArticleId>
            <ArticleId IdType="pubmed">23591914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. DPP-4 inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high fat diet consumption. Eur. J. Neurosci. 2013;37:839–849. doi: 10.1111/ejn.12088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejn.12088</ArticleId>
            <ArticleId IdType="pubmed">23240760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma M, et al.  DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc. Diabetol. 2015;14:1–13. doi: 10.1186/s12933-014-0162-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12933-014-0162-3</ArticleId>
            <ArticleId IdType="pmc">PMC4299541</ArticleId>
            <ArticleId IdType="pubmed">25582325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiciński, M. et al. Neuroprotective activity of sitagliptin via reduction of neuroinflammation beyond the incretin effect: Focus on Alzheimer’s disease. Bio. Med. Res. Inter., 6091014. 10.1155/2018/6091014 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA. Sitagliptin attenuates transient cerebral ischemia/reperfusion injury in diabetic rats: Implication of the oxidative–inflammatory–apoptotic pathway. Life Sci. 2015;126:81–86. doi: 10.1016/j.lfs.2015.01.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2015.01.030</ArticleId>
            <ArticleId IdType="pubmed">25721294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Újhelyi J, et al.  Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice. Reg. Peptide. 2014;194:23–29. doi: 10.1016/j.regpep.2014.09.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.regpep.2014.09.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzo MR, et al.  Dipeptidyl peptidase-4 inhibitors hale protective effect on cognitive impairment In aged diabetic patients with mild cognitive impairment. J. Gerontol. 2004;69:1122–1131. doi: 10.1093/gerona/glu032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/gerona/glu032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han R, et al.  BDNF alleviates neuroinflammation in the hippocampus of type 1 diabetic mice via blocking the aberrant HMGB1/RAGE/NF-κB pathway. Aging Dis. 2019;10:611–625. doi: 10.14336/AD.2018.0707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14336/AD.2018.0707</ArticleId>
            <ArticleId IdType="pmc">PMC6538223</ArticleId>
            <ArticleId IdType="pubmed">31165005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan W, et al.  Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling. J. Biol. Chem. 2003;278:23151–23162. doi: 10.1074/jbc.M212986200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M212986200</ArticleId>
            <ArticleId IdType="pubmed">12679365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, et al.  High glucose induces formation of tau hyperphosphorylation via Cav-1-mTOR pathway: a potential molecular mechanism for diabetes-induced cognitive dysfunction. Oncotarget. 2017;8:40843–40856. doi: 10.18632/oncotarget.17257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.17257</ArticleId>
            <ArticleId IdType="pmc">PMC5522306</ArticleId>
            <ArticleId IdType="pubmed">28489581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrillo-Sepulveda MA, Matsumoto T. Phenotypic modulation of mesenteric vascular smooth muscle cells from type 2 diabetic rats is associated with decreased caveolin-1 expression. Cell. Physiol. Biochem. 2014;34:1497–1506. doi: 10.1159/000366354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000366354</ArticleId>
            <ArticleId IdType="pubmed">25322824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonds JA, et al.  Depletion of caveolin-1 in type 2 diabetes model induces Alzheimer’s disease pathology precursors. J. Neurosci. 2019;39:8576–8583. doi: 10.1523/JNEUROSCI.0730-19.2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0730-19.2019</ArticleId>
            <ArticleId IdType="pmc">PMC6807274</ArticleId>
            <ArticleId IdType="pubmed">31527120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popiołek Ł, Biernasiuk A. Synthesis and investigation of antimicrobial activities of nitrofurazone analogues containing hydrazide-hydrazone moiety. Saudi Pharm. J. 2017;25:1097–1102. doi: 10.1016/j.jsps.2017.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jsps.2017.05.006</ArticleId>
            <ArticleId IdType="pmc">PMC5681330</ArticleId>
            <ArticleId IdType="pubmed">29158722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popiołek Ł, et al.  New hydrazide-hydrazones and 1,3-thiazolidin-4-ones with 3-hydroxy-2-naphthoic moiety: Synthesis, in vitro and in vivo studies. Biomed. Pharmacother. 2018;103:1337–1347. doi: 10.1016/j.biopha.2018.04.163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2018.04.163</ArticleId>
            <ArticleId IdType="pubmed">29864916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popiołek Ł, et al.  New hydrazide–hydrazones of isonicotinic acid: Synthesis, lipophilicity and in vitro antimicrobial screening. Chem. Biol. Drug. Des. 2018;91:915–923. doi: 10.1111/cbdd.13158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cbdd.13158</ArticleId>
            <ArticleId IdType="pubmed">29220872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popiołek Ł, Rysz B, Biernasiuk A, Wujec M. Synthesis of promising antimicrobial agents: Hydrazide-hydrazones of 5-nitrofuran-2-carboxylic acid. Chem. Biol. Drug. Des. 2020;95:260–269. doi: 10.1111/cbdd.13639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cbdd.13639</ArticleId>
            <ArticleId IdType="pubmed">31623022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall, C.S., &amp; Ballachey, E.L. A study of the rat’s behavior in a field: A contribution to method in comparative psychology. In University of California Publications in Psychology, 1–12 (University of California Press: Berkeley, CA, USA,1932).</Citation>
        </Reference>
        <Reference>
          <Citation>Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 2004;28:497–505. doi: 10.1016/j.neubiorev.2004.06.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2004.06.006</ArticleId>
            <ArticleId IdType="pubmed">15465137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melnikova T, et al.  Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neurosci. 2006;141:1149–1162. doi: 10.1016/j.neuroscience.2006.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2006.05.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Involvement of dopaminergic systems  Wang, D. et al. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25—35 i.c.v.-injected mice. Neuropsychopharmacol. 2007;32:1261–1271. doi: 10.1038/sj.npp.1301256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.npp.1301256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradford MM. A rapid sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye Binding. Anal. Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0003-2697(76)90527-3</ArticleId>
            <ArticleId IdType="pubmed">942051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Exalto, L. G., Whitmer, R. A, Kapele, L. J. &amp; Biessels, G. J. An update on type 2 diabetes, vascular dementia and Alzheimer’s disease. Exp. Gerontol. 47, 858–864 (2012).</Citation>
        </Reference>
        <Reference>
          <Citation>Srikanth V, et al.  Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol. Aging. 2011;32:763–777. doi: 10.1016/j.neurobiolaging.2009.04.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.04.016</ArticleId>
            <ArticleId IdType="pubmed">19464758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabet. Med. 2011;28:1463–1475. doi: 10.1111/j.1464-5491.2011.03464.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1464-5491.2011.03464.x</ArticleId>
            <ArticleId IdType="pubmed">21974744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correia SC, et al.  Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer’s disease and diabetes interrelation. Brain Res. 2012;1441:64–78. doi: 10.1016/j.brainres.2011.12.063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainres.2011.12.063</ArticleId>
            <ArticleId IdType="pubmed">22290178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr. Neurol. Neurosci. Rep. 2007;7:373–380. doi: 10.1007/s11910-007-0058-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-007-0058-7</ArticleId>
            <ArticleId IdType="pubmed">17764626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al.  High glucose-induced expression of inflammatory cytokines and reactive oxygen species in cultured astrocytes. Neuroscience. 2012;202:58–68. doi: 10.1016/j.neuroscience.2011.11.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2011.11.062</ArticleId>
            <ArticleId IdType="pubmed">22178606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc. Ther. 2012;30:49–59. doi: 10.1111/j.1755-5922.2010.00218.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1755-5922.2010.00218.x</ArticleId>
            <ArticleId IdType="pubmed">20718759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav. Immun. 2017;60:1–12. doi: 10.1016/j.bbi.2016.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2016.03.010</ArticleId>
            <ArticleId IdType="pubmed">26995317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halliday G, Robinson SR, Shepherd C, Kril J. Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol. 2000;27:1–8. doi: 10.1046/j.1440-1681.2000.03200.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1440-1681.2000.03200.x</ArticleId>
            <ArticleId IdType="pubmed">10696521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 2003;348:1356–1364. doi: 10.1056/NEJM2003ra020003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM2003ra020003</ArticleId>
            <ArticleId IdType="pubmed">12672864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012;379:2291–2299. doi: 10.1016/S0140-6736(12)60360-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)60360-2</ArticleId>
            <ArticleId IdType="pubmed">22683129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilliox LA, Chadrasekaran K, Kwan JY, Russell JW. Diabetes and cognitive impairment. Curr. Diab. Rep. 2016;16:1–11. doi: 10.1007/s11892-016-0775-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11892-016-0775-x</ArticleId>
            <ArticleId IdType="pubmed">26699764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moran, C. et al. Brain atrophy in type 2 diabetes. Regional distribution and influence on cognition. Diabetes Care.36, 4036–4042 (2013).</Citation>
        </Reference>
        <Reference>
          <Citation>Manschot SM, et al.  Utrecht Diabetic Encephalopathy Study Group Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes. 2006;55:1106–1113. doi: 10.2337/diabetes.55.04.06.db05-1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.55.04.06.db05-1323</ArticleId>
            <ArticleId IdType="pubmed">16567535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biessels, G. J. Cognition in type 2 diabetes: brain imaging correlates and vascular and metabolic risk factors in Diabetes, insulin and Alzheimer's disease, research and perspectives in Alzheimer's disease (ed. Craft, S., Christen, Y.) 81–88 (Springer-Verlag, 2010).</Citation>
        </Reference>
        <Reference>
          <Citation>Ramos-Rodriguez JJ, et al.  Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology. 2013;38:2462–2475. doi: 10.1016/j.psyneuen.2013.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.psyneuen.2013.05.010</ArticleId>
            <ArticleId IdType="pubmed">23790682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flood JF, Mooradian AD, Morley JE. Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes. 1990;39:1391–1398. doi: 10.2337/diab.39.11.1391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diab.39.11.1391</ArticleId>
            <ArticleId IdType="pubmed">2146179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roghani M, Joghataie MT, Jalali MR, Baluchnejadmojarad T. Time course of changes in passive avoidance and Y-maze performance in male diabetic rats. Iran. Biomed. J. 2006;10:99–104.</Citation>
        </Reference>
        <Reference>
          <Citation>Jabbarpour Z, et al.  Effect of tempol on the passive avoidance and novel object recognition task in diabetic rats. Brain Res. Bull. 2014;101:51–56. doi: 10.1016/j.brainresbull.2013.12.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.brainresbull.2013.12.013</ArticleId>
            <ArticleId IdType="pubmed">24412412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Rouen S, Dobrowsky RT. Hyperglycemia and downregulation of caveolin-1 enhance neuregulin-induced demyelination. Glia. 2008;56:877–887. doi: 10.1002/glia.20662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.20662</ArticleId>
            <ArticleId IdType="pmc">PMC2553896</ArticleId>
            <ArticleId IdType="pubmed">18338795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Taiji M. Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice. Biomed. Res. 2008;29:147–153. doi: 10.2220/biomedres.29.147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2220/biomedres.29.147</ArticleId>
            <ArticleId IdType="pubmed">18614848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conte M, et al.  Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer’s disease in comparison with healthy aging. GeroScience. 2021;43:985–1001. doi: 10.1007/s11357-020-00287-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11357-020-00287-w</ArticleId>
            <ArticleId IdType="pmc">PMC8110619</ArticleId>
            <ArticleId IdType="pubmed">33131010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ban K, et al.  Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340–2350. doi: 10.1161/CIRCULATIONAHA.107.739938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.739938</ArticleId>
            <ArticleId IdType="pubmed">18427132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry T, et al.  Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 2007;203:293–301. doi: 10.1016/j.expneurol.2006.09.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2006.09.028</ArticleId>
            <ArticleId IdType="pmc">PMC1850958</ArticleId>
            <ArticleId IdType="pubmed">17125767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Candeias E, et al.  Brain GLP-1/IGF-1 signaling and autophagy mediate exendin-4 protection against apoptosis in Type 2 diabetic rats. Mol. Neurobiol. 2018;55:4030–4050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28573460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oka JI, Goto N, Kameyama T. Glucagon-like peptide-1 modulates neuronal activity in the rat’s hippocampus. NeuroReport. 1999;10:1643–1646. doi: 10.1097/00001756-199906030-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001756-199906030-00004</ArticleId>
            <ArticleId IdType="pubmed">10501550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holscher C. Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014;221:31–41. doi: 10.1530/JOE-13-0221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JOE-13-0221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isacson R, et al.  The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharm. 2011;650:249–255. doi: 10.1016/j.ejphar.2010.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2010.10.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S, Sharma B. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Physiol. Behav. 2015;152:182–193. doi: 10.1016/j.physbeh.2015.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.physbeh.2015.09.007</ArticleId>
            <ArticleId IdType="pubmed">26382939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Batsh MM, Manal M, Shafik NM, Younos IH. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2015;769:297–305. doi: 10.1016/j.ejphar.2015.11.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2015.11.033</ArticleId>
            <ArticleId IdType="pubmed">26607467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowlands, J., Heng, J., Newsholme, P. &amp; Carless, R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signalling, Metabolism, and Function. Front. Endocrinol. (Lausanne)23, 672. 10.3389/fendo.2018.00672 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Hernandez PJ, Abel T. The role of protein synthesis in memory consolidation: Progress amid decades of debate. Neurobiol. Learn Mem. 2008;89:293–311. doi: 10.1016/j.nlm.2007.09.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nlm.2007.09.010</ArticleId>
            <ArticleId IdType="pmc">PMC2745628</ArticleId>
            <ArticleId IdType="pubmed">18053752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martínez-Moreno, A., Rodríguez-Durán, L. F. &amp; Escobar, M. L. Late protein synthesis-dependent phases in CTA long-term memory: BDNF requirement. Front Behav. Neurosci.5, 61. 10.3389/fnbeh.2011.00061 (2011).</Citation>
        </Reference>
        <Reference>
          <Citation>Bekinschtein P, Cammarota M, Medina JH. BDNF and memory processing. Neuropharmacology. 2014;76:677–683. doi: 10.1016/j.neuropharm.2013.04.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2013.04.024</ArticleId>
            <ArticleId IdType="pubmed">23688925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XM, Kim HP, Song R, Choi AMK. Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am. J. Resp. Cell Mol. Biol. 2006;34:434–442. doi: 10.1165/rcmb.2005-0376OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2005-0376OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korol SV, Jin Z, Babateen O, Birnir B. Glucagon-like peptide-1 (GLP-1) and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons. Diabetes. 2015;64:79–89. doi: 10.2337/db14-0668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/db14-0668</ArticleId>
            <ArticleId IdType="pubmed">25114295</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
